AI Article Synopsis
- * Although DCIS is often asymptomatic, it can sometimes present with nipple discharge or a lump, while benign conditions like intraductal papilloma may also cause similar symptoms.
- * A case study of a 72-year-old woman showed she had serous and bloody discharge, and the histological examination confirmed she had intermediate-grade DCIS alongside an intraductal papilloma.
Article Abstract
Ductal disease is a broad group encompassing both benign and malignant entities which may overlap clinically and radiologically. Ductal carcinoma in situ (DCIS) is a noninvasive breast malignancy accounting for 20% of newly diagnosed breast cancer cases. It involves malignant epithelial cells confined to the duct(s). Although they are commonly diagnosed incidentally on screening mammography, DCIS may present with nipple discharge or a palpable lump. Benign diseases of the duct include intraductal papilloma and may present similarly with bloody or serous nipple discharge. Imaging evaluation will help in differentiating between the 2 entities and pathological examination will provide the final diagnosis. We present a case of a 72-year-old female who was presented with serous and bloody discharge and histology revealed intermediate grade ductal carcinoma in situ involving an intraductal papilloma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691407 | PMC |
| http://dx.doi.org/10.1016/j.radcr.2022.11.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Radiological images of an advanced invasive carcinoma with mucinous aspects: A case report.
Radiol Case Rep
March 2025
Diagnostic Imaging Unit, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Viale Oxford 81, Rome, Italy.
Mucinous carcinoma of the breast, also known as colloid carcinoma, is an uncommon type of differentiated adenocarcinoma, representing only 2% of all invasive breast carcinomas. It usually occurs in women ≥ 60 years of age. Mucinous carcinoma is characterized by clusters of epithelial tumour cells suspended in pools of extracellular mucin and is further divided in 2 subgroups, pure and mixed.
View Article and Find Full Text PDFA morphometric signature to identify ductal carcinoma in situ with a low risk of progression.
NPJ Precis Oncol
January 2025
Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Ductal carcinoma in situ (DCIS) may progress to ipsilateral invasive breast cancer (iIBC), but often never will. Because DCIS is treated as early breast cancer, many women with harmless DCIS face overtreatment. To identify features associated with progression, we developed an artificial intelligence-based DCIS morphometric analysis pipeline (AIDmap) on hematoxylin-eosin-stained (H&E) tissue sections.
View Article and Find Full Text PDFThe Role of Tumor-Associated Neutrophils in Early Luminal HER2-Negative Breast Cancer Progression.
Asian Pac J Cancer Prev
January 2025
S.P. Botkin City Clinical Hospital, Moscow, Russia.
Objectives: To study the predictive role of tumor-associated neutrophils in early luminal HER2-negative breast cancer.
Materials And Methods: This is a retrospective study conducted on 60 women cases aged from 31 to 79 years underwent surgery for luminal HER2-negative ductal breast cancer in tertiary care cancer centre. We first estimated basic morphological signs: tumor size, tumor grade (by Nottingham Histologic Score), tumor infiltrating lymphocytes (TILs), Lymphovascular invasion, hormonal receptors status, proliferative index, and regional lymph nodes metastasis.
Preoperative MRI to Predict Upstaging of DCIS to Invasive Cancer at Surgery.
Ann Surg Oncol
January 2025
Department of Radiology, University of Washington, Seattle, WA, USA.
Background: Ductal carcinoma in situ (DCIS) is overtreated, in part because of inability to predict which DCIS cases diagnosed at core needle biopsy (CNB) will be upstaged at excision. This study aimed to determine whether quantitative magnetic resonance imaging (MRI) features can identify DCIS at risk of upstaging to invasive cancer.
Methods: This prospective observational clinical trial analyzed women with a diagnosis of DCIS on CNB.
Effects of NK cell-related lncRNA on the immune microenvironment and molecular subtyping for pancreatic ductal adenocarcinoma.
Front Immunol
January 2025
Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Background: Patients with pancreatic ductal adenocarcinoma (PDAC) face a highly unfavorable outcome and have a poor response to standard treatments. Immunotherapy, especially therapy based on natural killer (NK) cells, presents a promising avenue for the treatment of PDAC.
Aims: This research endeavor seeks to formulate a predictive tool specifically designed for PDAC based on NK cell-related long non-coding RNA (lncRNA), revealing new molecular subtypes of PDAC to promote personalized and precision treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!